5 / 27
1. Lenvatinib EMA SmPC (Lenvima®; Eisai Europe Ltd). Available at:
https://www.ema.europa.eu/ .Accessed on 21 Jan 2019.
2. Lenvatinib EMA SmPC (Kisplyx®; Eisai Europe Ltd). Available at:
http://www.ema.europa.eu/. Accessed on 21 Jan 2019.
Lenvatinib – Approved Indications
LENVIMA®
is indicated as monotherapy for the treatment of adult
patients with progressive, locally advanced or metastatic, differentiated
(papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to
radioactive iodine (RAI).
1
KISPLYX®
is indicated in combination with everolimus for the treatment
of adult patients with advanced renal cell carcinoma (RCC) following
one prior vascular endothelial growth factor (VEGF)-targeted therapy.
2
LENVIMA®
is indicated as monotherapy for the treatment of adult
patients with advanced or unresectable hepatocellular carcinoma
(HCC) who have received no prior systemic therapy.
1